Effect of pembrolizumab on CD4+ CD25+ , CD4+ LAP+ and CD4+ TIM-3+ T cell subsets

Novel effector phenotype of Tim-3+ regulatory T cells leads to enhanced suppressive function in head and neck cancer patients

(2018) Zhuqing Liu et al.   CLINICAL CANCER RESEARCH

FOXP3+ Treg as a therapeutic target for promoting anti-tumor immunity

(2018) Theresa L. Whiteside   EXPERT OPINION ON THERAPEUTIC TARGETS

Acute stimulation generates Tim-3-expressing T helper type 1 CD4 T cells that persist in vivo and show enhanced effector function

(2018) Jacob V. Gorman et al.   IMMUNOLOGY

Anti-CTLA-4 antibodies in cancer immunotherapy: selective depletion of intratumoral regulatory T cells or checkpoint blockade?

(2018) Fei Tang et al.   Cell and Bioscience

Immune checkpoint inhibitors in cancer therapy: a focus on T-regulatory cells

(2017) Varun Sasidharan Nair et al.   IMMUNOLOGY AND CELL BIOLOGY

De-novo and acquired resistance to immune checkpoint targeting

(2017) Nicholas L Syn et al.   LANCET ONCOLOGY

Proliferation of PD-1+ CD8 T cells in peripheral blood after PD-1–targeted therapy in lung cancer patients

(2017) Alice O. Kamphorst et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

T Cell Fate at the Single-Cell Level

(2016) Veit R. Buchholz et al.   Annual Review of Immunology

Lag-3, Tim-3, and TIGIT: Co-inhibitory Receptors with Specialized Functions in Immune Regulation

(2016) Ana C. Anderson et al.   IMMUNITY

PD-1 Blockade Expands Intratumoral Memory T Cells

(2016) A. Ribas et al.   Cancer Immunology Research

Tumor-infiltrating Tim-3+ T cells proliferate avidly except when PD-1 is co-expressed: Evidence for intracellular cross talk

(2016) Jing Li et al.   OncoImmunology

Ipilimumab-dependent cell-mediated cytotoxicity of regulatory T cells ex vivo by nonclassical monocytes in melanoma patients

(2015) Emanuela Romano et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

T-cell exhaustion in the tumor microenvironment

(2015) Y Jiang et al.   Cell Death & Disease

Helios, and not FoxP3, is the marker of activated Tregs expressing GARP/LAP

(2015) Eyad Elkord et al.   Oncotarget

Fc-dependent depletion of tumor-infiltrating regulatory T cells co-defines the efficacy of anti–CTLA-4 therapy against melanoma

(2013) Tyler R. Simpson et al.   JOURNAL OF EXPERIMENTAL MEDICINE

Anti-CTLA-4 Antibodies of IgG2a Isotype Enhance Antitumor Activity through Reduction of Intratumoral Regulatory T Cells

(2013) M. J. Selby et al.   Cancer Immunology Research

Tim-3: An Activation Marker and Activation Limiter of Innate Immune Cells

(2013) Gencheng Han et al.   Frontiers in Immunology

The immunosuppressive tumour network: myeloid-derived suppressor cells, regulatory T cells and natural killer T cells

(2012) Dennis Lindau et al.   IMMUNOLOGY

Modulation of Lymphocyte Regulation for Cancer Therapy: A Phase II Trial of Tremelimumab in Advanced Gastric and Esophageal Adenocarcinoma

(2010) C. Ralph et al.   CLINICAL CANCER RESEARCH

Tremelimumab (anti-CTLA4) mediates immune responses mainly by direct activation of T effector cells rather than by affecting T regulatory cells

(2010) Sameena Khan et al.   CLINICAL IMMUNOLOGY

Interleukin-2 Receptor Signaling: At the Interface between Tolerance and Immunity

(2010) Thomas R. Malek et al.   IMMUNITY

Targeting Tim-3 and PD-1 pathways to reverse T cell exhaustion and restore anti-tumor immunity

(2010) Kaori Sakuishi et al.   JOURNAL OF EXPERIMENTAL MEDICINE

T Cell Activation

(2009) Jennifer E. Smith-Garvin et al.   Annual Review of Immunology

PD-1 and Its Ligands in Tolerance and Immunity

(2008) Mary E. Keir et al.   Annual Review of Immunology